Joanna Brewer, Ph.D.
About Joanna Brewer, Ph.D.
Joanna Brewer, Ph.D., is the Chief Scientific Officer at Adaptimmune, known for her pivotal role in advancing allogeneic T-cell therapies and building the Allogeneic Research organization.
Joanna Brewer, Ph.D. - Chief Scientific Officer
Joanna Brewer, Ph.D., currently holds the position of Chief Scientific Officer at Adaptimmune. She has been a key figure in the company's scientific endeavors, significantly contributing to the development and advancement of innovative T-cell therapies. Dr. Brewer transitioned to this role after serving as Senior Vice President of Allogeneic Research. Her leadership has been pivotal in steering the company's research direction and building a robust scientific team.
Joanna Brewer, Ph.D. - Education and Expertise
Joanna Brewer, Ph.D., possesses a rich academic background with a master's degree in Natural Sciences and a Ph.D. in cellular signalling from the University of Cambridge, U.K. Her education has provided her with a strong foundation in the life sciences, particularly in cellular mechanisms and therapeutic development. Dr. Brewer's expertise is recognized within the field of T-cell therapy, where she has driven substantial advancements.
Joanna Brewer, Ph.D. - Background in Research and Development
Dr. Joanna Brewer has a significant background in research and development within the biotechnology field. She was a founding scientist at Adaptimmune and has been instrumental in building multiple research teams dedicated to the development of SPEAR T-cell therapies. Her previous experience includes key positions at Avidex, Medigene, and Immunocore, where she contributed to various therapeutic research projects.
Joanna Brewer, Ph.D. - Achievements in Allogeneic Research
In her role as Senior Vice President of Allogeneic Research since December 2019, Dr. Joanna Brewer built the Allogeneic Research organization from the ground up. She transformed the concept of iPSC-derived allogeneic T-cell therapies from a theoretical idea into a tangible potential candidate for clinical application. This achievement marks a significant milestone in the field of cell therapy, showcasing her ability to drive innovation and lead complex research projects.